High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

Inclusion Criteria: * Diagnosed of congenital haemophilia A or B with inhibitors to factor VIII or IX, respectively * A history of 3 or more joint bleeds during the last 12 months Exclusion Criteria: * Joint bleeding within 7 days prior to trial start * Treatment for bleeds within the last 5 days prior to trial start * Clinically relevant coagulation disorders other than congenital haemophilia A or B